{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:17:17Z","timestamp":1746591437440,"version":"3.40.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,6]]},"DOI":"10.7759\/cureus.83570","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T13:06:44Z","timestamp":1746536804000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of Direct Oral Anticoagulants in Patients With Upper Extremity Deep Vein Thrombosis: A Meta-Analysis of Efficacy and Safety"],"prefix":"10.7759","author":[{"given":"Ayman","family":"Zyada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Fakhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohiel","family":"Nagib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Alnadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abouelseoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahma","family":"Seken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Jabr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male C","year":"2020","unstructured":"Male C, Lensing AWA, Palumbo JS, et al.. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020, 7:18-27. 10.1016\/S2352-3026(19)30219-4","journal-title":"Lancet Haematol"},{"key":"ref2","article-title":"Apixaban","author":"Agrawal A","year":"2025","unstructured":"Agrawal A, Kerndt CC, Manna B. Apixaban. StatPearls [Internet], StatPearls Publishing, Treasure Island (FL): StatPearls Publishing; 2025."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3400\/avd.oa.23-00005","article-title":"Risk and prognosis of upper extremity deep vein thrombosis","volume":"16","author":"Endo Y","year":"2023","unstructured":"Endo Y, Unno N, Yamamoto N, et al.. Risk and prognosis of upper extremity deep vein thrombosis. Ann Vasc Dis. 2023, 16:200-4. 10.3400\/avd.oa.23-00005","journal-title":"Ann Vasc Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-05-0352","article-title":"Diagnosis and management of upper extremity deep-vein thrombosis in adults","volume":"108","author":"Grant JD","year":"2012","unstructured":"Grant JD, Stevens SM, Woller SC, et al.. Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thromb Haemost. 2012, 108:1097-108. 10.1160\/TH12-05-0352","journal-title":"Thromb Haemost"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos SK","year":"2021","unstructured":"Kakkos SK, Gohel M, Baekgaard N, et al.. Editor's choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021, 61:9-82. 10.1016\/j.ejvs.2020.09.023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon C","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, et al.. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141:e419S-96S. 10.1378\/chest.11-2301","journal-title":"Chest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2020.02.024","article-title":"Midterm outcomes in patients with upper extremity deep vein thrombosis","volume":"8","author":"Beiswenger AC","year":"2020","unstructured":"Beiswenger AC, Quereshy HA, Rouabhi M, et al.. Midterm outcomes in patients with upper extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2020, 8:930-938.e2. 10.1016\/j.jvsv.2020.02.024","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.04.003","article-title":"A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (catheter 2)","volume":"162","author":"Davies GA","year":"2018","unstructured":"Davies GA, Lazo-Langner A, Gandara E, et al.. A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (catheter 2). Thromb Res. 2018, 162:88-92. 10.1016\/j.thromres.2017.04.003","journal-title":"Thromb Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.07.041","article-title":"Rivaroxaban in the treatment of PICC-associated upper extremity venous thrombosis","volume":"39","author":"Fan F","year":"2017","unstructured":"Fan F, Zou Y, Zhang S, et al.. Rivaroxaban in the treatment of PICC-associated upper extremity venous thrombosis. Clin Ther. 2017, 39:1882-8. 10.1016\/j.clinthera.2017.07.041","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/0268355520967519","article-title":"The treatment of upper extremities deep vein thrombosis related to thoracic outlet syndrome with direct oral anticoagulants","volume":"36","author":"Fiori L","year":"2021","unstructured":"Fiori L, Serrao A, Ferretti A, Chistolini A. The treatment of upper extremities deep vein thrombosis related to thoracic outlet syndrome with direct oral anticoagulants. Phlebology. 2021, 36:329-30. 10.1177\/0268355520967519","journal-title":"Phlebology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25820","article-title":"Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban","volume":"95","author":"Houghton DE","year":"2020","unstructured":"Houghton DE, Casanegra AI, Peterson LG, et al.. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. Am J Hematol. 2020, 95:817-23. 10.1002\/ajh.25820","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24588","article-title":"Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban","volume":"92","author":"Laube ES","year":"2017","unstructured":"Laube ES, Mantha S, Samedy P, Wills J, Harnicar S, Soff GA. Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban. Am J Hematol. 2017, 92:E9-10. 10.1002\/ajh.24588","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-017-0149-x","article-title":"Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis","volume":"15","author":"Montiel FS","year":"2017","unstructured":"Montiel FS, Ghazvinian R, Gotts\u00e4ter A, Elf J. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J. 2017, 15:26. 10.1186\/s12959-017-0149-x","journal-title":"Thromb J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02044-4","article-title":"Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience","volume":"50","author":"Porfidia A","year":"2020","unstructured":"Porfidia A, Agostini F, Giarretta I, et al.. Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. J Thromb Thrombolysis. 2020, 50:355-60. 10.1007\/s11239-020-02044-4","journal-title":"J Thromb Thrombolysis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.07.008","article-title":"Rivaroxaban in the treatment of upper extremity deep vein thrombosis: a single-center experience and review of the literature","volume":"181","author":"Schastlivtsev I","year":"2019","unstructured":"Schastlivtsev I, Lobastov K, Tsaplin S, et al.. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: a single-center experience and review of the literature. Thromb Res. 2019, 181:24-8. 10.1016\/j.thromres.2019.07.008","journal-title":"Thromb Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.07.005","article-title":"Upper extremities deep vein thrombosis treated with oral direct anticoagulants: a prospective cohort study","volume":"339","author":"Vedovati MC","year":"2021","unstructured":"Vedovati MC, Tratar G, Mavri A, et al.. Upper extremities deep vein thrombosis treated with oral direct anticoagulants: a prospective cohort study. Int J Cardiol. 2021, 339:158-63. 10.1016\/j.ijcard.2021.07.005","journal-title":"Int J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1432","article-title":"Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry","volume":"133","author":"Mu\u00f1oz FJ","year":"2008","unstructured":"Mu\u00f1oz FJ, Mismetti P, Poggio R, Valle R, Barr\u00f3n M, Guil M, Monreal M. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest. 2008, 133:143-8. 10.1378\/chest.07-1432","journal-title":"Chest"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13715","article-title":"Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis","volume":"15","author":"van Rein N","year":"2017","unstructured":"van Rein N, Biedermann JS, van der Meer FJ, et al.. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis. J Thromb Haemost. 2017, 15:1386-91. 10.1111\/jth.13715","journal-title":"J Thromb Haemost"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/359063-use-of-direct-oral-anticoagulants-in-patients-with-upper-extremity-deep-vein-thrombosis-a-meta-analysis-of-efficacy-and-safety","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T13:06:44Z","timestamp":1746536804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/359063-use-of-direct-oral-anticoagulants-in-patients-with-upper-extremity-deep-vein-thrombosis-a-meta-analysis-of-efficacy-and-safety"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.83570","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}